key: cord-0949701-t8c4tzln
authors: Barmettler, Sara; DiGiacomo, Daniel V.; Yang, Nancy J.; Lam, Tiffany; Naranbhai, Vivek; Dighe, Anand S.; Burke, Kristin E.; Blumenthal, Kimberly G.; Ling, Morris; Hesterberg, Paul E.; Saff, Rebecca R.; MacLean, James; Ofoman, Onosereme; Berrios, Cristhian; St Denis, Kerri J.; Lam, Evan C.; Gregory, David; Iafrate, Anthony John; Poznansky, Mark; Lee, Hang; Balazs, Alejandro; Pillai, Shiv; Farmer, Jocelyn R.
title: Response to SARS-CoV-2 Initial Series and Additional Dose Vaccine in Patients with Predominant Antibody Deficiency
date: 2022-04-02
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2022.03.017
sha: bc6e48d8e735c9b8fbfe4d93dc6285da21547aae
doc_id: 949701
cord_uid: t8c4tzln

Background SARS-CoV-2 infection in patients with predominant antibody deficiency (PAD) is associated with high morbidity, yet data regarding response to SARS-CoV-2 immunization in PAD patients, including additional dose vaccine, is limited. Objective We sought to characterize antibody response to SARS-CoV-2 vaccine in PAD patients and define correlates of vaccine response. Methods We assessed levels and function of anti-SARS-CoV-2 antibodies in 62 PAD patients compared to matched healthy controls at baseline, at 4-6 weeks following initial series immunization - a single dose of Ad26.COV2.S (Janssen) or two doses of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) - and at 4-6 weeks following additional dose immunization, if received. Results Following initial series SARS-CoV-2 vaccination, PAD patients had lower mean anti-spike antibody levels compared to matched healthy controls (140.1 U/mL vs. 547.3 U/mL; p=0.02). Patients with secondary PAD (e.g., use of B-cell depletion therapy) and patients with severe primary PAD (e.g., common variable immunodeficiency with autoinflammatory complications) had the lowest mean anti-spike antibody levels. Immune correlates of a low anti-spike antibody response included low CD4+ helper T cells, low CD19+ total B cells, and low class-switched memory (CD27+IgD/M-) B cells. Additionally, a low (< 100 U/mL) anti-spike antibody response was associated with prior exposure to B-cell depletion therapy, both at any time in the past (OR 5.5; CI 1.5-20.4; p=0.01) and proximal to vaccination (OR 36.4; CI 1.7-791.9; p=0.02). Additional dose immunization with an mRNA vaccine in a subset of 31 PAD patients increased mean anti-spike antibody levels (76.3 U/mL pre- to 1065 U/mL post-additional dose; p<0.0001). Conclusions Patients with secondary and severe primary PAD, characterized by low helper T cells, low B cells, and/or low class-switched memory B cells, were at risk for low antibody response to SARS-CoV-2 immunization, which improved following additional dose vaccination in the majority of patients.

Board-approved protocol (#2021P002414). Antibody response to the SARS-CoV-2 vaccine in 152 patients with known PAD was evaluated. Inclusion criteria were: Adult PAD patients 153 longitudinally followed at Mass General Brigham who underwent initial series SARS-CoV-2 154 vaccination between December 16, 2020 and June 9, 2021 as well as PAD patients who had 155 clinically obtained testing during this same time period. Patients who received additional CoV-2 vaccines after their primary series were assessed longitudinally. Exclusion criteria were: 157 J o u r n a l P r e -p r o o f 8 PAD patients with any prior positive polymerase chain reaction (PCR) testing for SARS-CoV-2. 158 PAD diagnoses were confirmed by manual chart review by a clinical immunologist and met 159 consensus definitions (16, 18, 19) . Patients with any confounding variables at the time of 160 immunodeficiency diagnosis (e.g., clonal lymphocyte population or ongoing immunosuppression 161 without potential for discontinuation) were considered secondary PAD. Patients with primary 162 PAD were further subclassified as mild (IgG subclass deficiency, specific antibody deficiency 163 (SAD), and primary hypogammaglobulinemia), moderate (uncomplicated common variable 164 immunodeficiency (CVID), defined as an absence of co-occurring autoinflammatory clinical 165 features (20)), and severe (complicated PAD that encompassed the diagnoses of activated PI3K-166 delta syndrome (APDS), TACI deficiency, NFKB1 deficiency, and complicated CVID/SAD 167 (CVIDc/SADc), defined as a presence of co-occurring autoinflammatory clinical features (20) 168 but without a known genetic etiology). We evaluated demographic information and clinical 169 characteristics including type of PAD, vaccine type received, previous genetic testing if 170 performed/available, and previous immune testing performed including native antibody levels, 171 native antibody responses to vaccines (e.g. pneumovax23, Hemophilus influenza B [HIB] , 172 tetanus, diphtheria and pertussis [Tdap] ), peripheral blood lymphocyte counts, and T-cell 173 functional studies, as available. We evaluated previous and current treatment regimens with a 174 focus on immunoglobulin replacement type, if received, and other immunosuppressants or 175 biologics received in the past or in close proximity to vaccination (defined as six months prior to 176 one month post immunization). 177

Serologic assays were performed through Massachusetts General Pathology Laboratory 178 using the Roche Elecsys Anti-SARS-CoV-2 S-antibody test (evaluating antibodies to the SARS-179

CoV-2 spike (S) protein receptor binding domain; 'anti-spike antibody') and the Roche Elecsys 180 9 Anti-SARS-CoV-2 N-antibody test (evaluating antibodies to the SARS-CoV-2 nucleocapsid 181 domain 'anti-nucleocapsid antibody'). These tests are semiquantitative and have been correlated 182 with neutralizing immunity (21, 22) . The Roche S-antibody assay reports results in absorbance 183 units per mL (U/mL) with values ≥ 0.8 U/mL considered reactive (23). We further delineated a 184 minimum threshold protective anti-spike antibody response as ≥ 100 U/mL, which has been 185 correlated with a detectable level of pseudovirus neutralization in healthy control subjects (24). 186

The Roche N-antibody assay reports a cutoff index (COI) with values ≥ 1.00 COI considered 187 reactive. 188

Neutralization was measured using a SARS-CoV-2 pseudovirus neutralization assay that 189 has been previously described (25). Briefly, lentiviral particles encoding both luciferase and 190

ZsGreen reporter genes were pseudotyped with SARS-CoV-2 spike protein and produced in 191 293T cells, titered using ZsGreen expression by flow cytometry and used in an automated 192 neutralization assay with 50-250 infectious units of pseudovirus co-incubated with three-fold 193 serial dilutions of serum for 1 hour. Neutralization was determined on Percent neutralization was determined by subtracting background luminescence measured in cell 195 control wells (cells only) from sample wells and dividing by virus control wells (virus and cells 196 only) . pNT50 values were calculated by taking the inverse of the 50% inhibitory concentration. 197

Quantitative detection of total (IgA/M/G) and individual isotype (IgG, IgA or IgM) 198 antibodies to SARS-CoV-2 receptor binding domain (RBD) was performed by enzyme linked 199 immunosorbent assay (ELISA) as previously described (24, 26) . 200 PAD participants were matched on age (+/-10 years) and time from the most recent 201 vaccination (+/-14 days) at a ratio of 1:1 to healthy controls. The control population was healthy, 202 ambulatory adults sampled in August 2020 or early 2021, consented under IRB protocols 203 J o u r n a l P r e -p r o o f 10 (#2020P001081 and 2020P002274), as described previously (24) Antibody response to the SARS-CoV-2 vaccine is lower among patients with PAD compared to 219 healthy controls. 220 101 individuals with PAD met criteria for this study ( Figure E1) . 62 of the 101 met 221 criteria for case-control matching based on age (+/-10 years) and time from the most recent 222 vaccination (+/-14 days) at a ratio of 1:1 case to control, and these 62 patients were used for all 223 subsequent analyses ( Table 1) . The mean age of the 62 patient PAD cohort was 52.5 years. 224

There were 43 women (69.4%) and 19 men (30.6%). There were no statistically significant 225 differences between PAD and healthy control groups in terms of age, gender, and time between 226 J o u r n a l P r e -p r o o f 11 blood draw and the most recent vaccination. The PAD group consisted of more non-Hispanic 227 white patients (95.2%) than the control population (p<0.01). Among both groups, most 228 participants had received the mRNA-1273 (Moderna) vaccine (PAD: 53.2% vs. healthy control: 229 54.8%), followed by the BNT162b2 (Pfizer) vaccine (PAD: 40.3% vs. healthy control: 24.9%), 230 followed by the Ad26.COV2.S (Janssen) vaccine (PAD: 6.5% vs. healthy control: 20.9%) 231 (p=0.05). 232

We observed significantly lower mean anti-spike antibody levels in PAD patients 233 compared to matched healthy controls following initial series SARS-CoV-2 vaccination (anti-234 spike antibody level for all vaccine types 140.1 vs. 547.3 U/mL; p=0.02) (Table 2, Fig. 1A) . 235

The odds of mounting a protective anti-spike antibody response ≥ 100 U/mL were 2.5 times 236 higher in healthy controls than those diagnosed with PAD. In evaluating response to the specific 237 SARS-CoV-2 vaccine received, PAD patients had significantly lower antibody responses 238 compared to matched healthy controls following immunization with mRNA-1273 (Moderna) and 239

Ad26.COV2.S (Janssen) (Table 2, Fig. 1B) . Overall, SARS-CoV-2 anti-spike antibody titers 240 were significantly higher in PAD patients who had received either mRNA vaccine platform as 241 compared to the Ad26.COV2.S (Janssen) vaccine (Fig. 1C) . 242 243 Antibody response to SARS-CoV-2 vaccine is lower among PAD patients with 244 secondary and severe primary immunodeficiency. 245

To determine whether anti-spike antibody responses correlated with clinical diagnosis, 246 we subcategorized our PAD cohort ( Table 3 ). Ten patients met criteria for secondary PAD due 247

to the presence of a potentially confounding immunosuppressive variable at the time of immune 248 deficiency diagnosis. 52 patients had no confounding variables at the time of diagnosis and met 249 12 criteria for primary PAD. We further subcategorized primary PAD patients by underlying 250 degree of humoral immune dysfunction. Immunologic testing including native immunoglobulin 251 levels (prior to immunoglobulin replacement therapy), antibody titers to T cell-dependent and T 252 cell-independent immunizations, peripheral lymphocyte flow cytometry (including analysis of B 253 cell and T cell maturation), and T cell functional testing of T cell receptor, mitogen, and antigen 254 stimuli for this cohort are detailed in Table E1 . Primary PAD participants were classified as mild 255 IgM, in post-immunization serum available in 36 PAD patients. Overall, we observed linear 265 correlations between anti-spike antibody levels and pseudovirus neutralization function and anti-266 RBD antibody levels, respectively, among PAD patients (Fig. 3) . Similar to the observed 267 difference in anti-spike antibody levels, patients with secondary PAD trended towards lower 268 SARS-CoV-2 vaccine response by pseudovirus neutralization and total anti-RBD antibody levels 269 compared to patients with primary PAD ( Table 4 Fig. 2A ). There was no statistically significant difference in anti-spike antibody 274 responses further delineated by sub-categorized clinical entity within the mild and severe disease 275 subtypes ( Fig. 2A) . Analysis of pseudovirus neutralization showed a similar trend, with 276 significantly lower mean neutralization function in severe as compared to mild PAD patients 277 (severe: 43.4 vs. mild: 389, pNT50; p=0.01) ( Table 4 Within our PAD cohort, we analyzed underlying immunophenotypic correlates of a 285 severely low antibody response to SARS-CoV-2 immunization, defined as an anti-spike antibody 286 level < 100 U/mL. PAD patients with anti-spike antibody levels < 100 U/mL had lower native 287 antibody levels, including IgG, IgA, and IgM, and lower native HIB vaccine levels ( Table 5) . In 288 addition, PAD patients with anti-spike antibody levels < 100 U/mL had lower absolute 289 circulating counts of total CD3+ T cells, CD4+ helper T cells, and total CD19+ B cells. Finally, 290 PAD patients with anti-spike antibody levels < 100 U/mL had demonstration of impaired B-cell-291 maturation. Specifically, patients with <5% memory (CD27+ as % CD19+) B cells in circulation 292 and <2% class-switched memory (CD27+IgM/D-as % CD19+) B cells in circulation were at an 293 increased risk of having an anti-spike antibody level < 100 U/mL (OR 9.7; 95% CI 1.9-49.9; 294 p<0.01 and OR 2.3; 95%CI 0.6-9; p<0.01, respectively). 295 J o u r n a l P r e -p r o o f 14 296

Passive transfer of anti-spike antibodies in patients receiving immunoglobulin replacement 297 therapy occurred at a low level. 298

Despite exclusion in this study of PAD patients with any prior positive PCR testing for 299 SARS-CoV-2, mean anti-nucleocapsid antibody levels were higher in PAD patients actively 300 receiving intravenous immunoglobulin (IVIG) therapy (1.15 COI), compared to subcutaneous 301 immunoglobulin (SCIG) therapy (0.19 COI), compared to no replacement immunoglobulin 302 therapy (0.09 COI) (p=0.047; Table E2 ). These data were consistent with low levels of passively 303 transferred anti-SARS-CoV-2 antibodies in immunoglobulin replacement products as previously 304

described (27). 305

To determine whether passive antibody transfer could be confounding the anti-spike 306 antibody analysis, we analyzed anti-spike antibodies at pre-vaccination timepoints in PAD 307 patients on replacement immunoglobulin therapy, as available (n=16) (Fig. 4A) . At the median 308 time of final blood draw for this study, detection of passively transferred anti-spike antibodies 309 was extremely low (anti-spike antibody levels > 1 U/mL, > 10 U/mL, and > 100 U/mL were seen 310 in 82.7%, 37.8%, and 0.0% of unvaccinated PAD subjects receiving immunoglobulin 311 replacement, respectively). These data suggested limited confounding of passively received anti-312 spike antibodies, particularly using a threshold response anti-spike antibody level > 100 U/mL. 313

Moreover, PAD patients who mounted an anti-spike level > 100 U/mL did not differ by 314 immunoglobulin treatment status or dose per body weight (mg/kg) per month of immunoglobin 315 therapy, if received (Fig. 4B) . Instead, as noted above, differences in response to vaccine did 316 correlate with underlying immunophenotypes including lower native immunoglobulin levels, 317 lower native HIB vaccine titer, lower absolute CD3+ T cells, CD4+ T cells, and CD19+ B cells, 318 and lower absolute and percent class-switched memory B cells in circulation ( Figure 4C) . 319 320 Immunosuppression associated with low anti-spike antibody response among patients with PAD. 321 PAD patients who received any immunosuppression in the one month prior to SARS-322 CoV-2 immunization had a lower mean anti-spike antibody response (30.1 vs. 276.5 U/mL; 323 p=0.02) ( Table 6 ). Receiving any immunosuppression in the one month following SARS-CoV-324 2 immunization also trended towards a lower mean anti-spike antibody level among PAD 325 patients (39.1 vs. 258.4 U/mL; p=0.07). Finally, PAD patients who had any previous use of a B-326 cell depletion agent (e.g., rituximab) had a lower mean anti-spike antibody response (11.6 vs. 327 289.8 U/mL; p<0.01) and an increased odds of mounting an anti-spike antibody response < 100 328 U/mL (OR 5.5; CI 1.5-20.4; p=0.01). This association became more pronounced when 329 accounting for patients who received a B-cell depletion agent proximal to the time of 330 immunization, which we defined as between 6 months prior to one month post-initial 331 immunization. Specifically, PAD patients who had proximal use of a B-cell depletion agent had 332 a lower mean anti-spike antibody response (0.67 vs. 308.8 U/mL; p<0.01) and an increased odds 333 of mounting an anti-spike antibody response < 100 U/mL (OR 36.4; CI 1.7-791.9; p=0.02). This is the largest case-to-control matched immunodeficiency patient cohort evaluating 359 response to SARS-CoV-2 vaccination to date and the first study evaluating additional vaccine 360 doses in patients with PAD. As SARS-CoV-2 infection in patients with PAD is associated with 361 high morbidity, an improved understanding of the effectiveness of SARS-CoV-2 immunization 362 in immunodeficient patients is critical. 363

In this study, we found that approximately 60% of PAD patients were able to develop 364 anti-spike antibody responses ≥ 100 U/mL following initial series SARS-CoV-2 vaccination. 365

However, compared to healthy controls matched for age and time from immunization, PAD 366 patients had significantly lower mean anti-spike antibody levels. Underlying PAD diagnosis and 367 immunophenotypic markers of disease severity correlated with response to vaccination. 368

Specifically, anti-spike antibody levels were lowest in those patients with secondary and severe 369 primary PAD (such as complicated CVID) as compared to those with mild PAD (such as IgG 370 subclass deficiency, SAD, and primary hypogammaglobulinemia). Certain immunophenotypic 371 markers correlated with a lower anti-spike antibody response, including low native antibody 372 levels (IgG, IgA, and IgM), low native IgG antibodies for HIB, low CD4+ helper T cells, low 373 CD19+ total B cells, and low class-switched memory (CD27+IgD/M-) B cells. These clinical 374 diagnostic and immunophenotypic risk factors may help clinicians to better stratify their patients 375 with predominant antibody deficiency in terms of identifying those patients at highest risk for a 376 low antibody response following SARS-CoV-2 immunization. 377 378 Many patients with PAD will require secondary immunosuppression to manage 379 autoimmune and/or autoinflammatory disease co-morbidities (28). Here secondary 380 immunosuppression, and in particular use of a B-cell depleting agent, most frequently rituximab, 381 was associated with a decreased humoral immune response to SARS-CoV-2 vaccination. Prior 382 B-cell depleting agent use correlated with severely low (< 100 U/mL) mean anti-spike antibody 383 levels in this study. These data are consistent with prior reports of lower SARS-CoV-2 vaccine 384 antibody responses following B-cell depleting therapy in other immunodeficient patient 385 demographics (4, 29), and suggest that this patient population should maintain increased 386 precautions and vigilance regarding potential COVID-19 exposures. Overall, these data highlight 387 the unique risk for patients with primary immunodeficiency related to SARS-CoV-2 vaccination, 388 both the potential for diminished immune response due to a congenital immunodeficiencyand 389 the potential for diminished immune response related to use of secondary immunosuppression. 390 391 In PAD patients who received an additional SARS-CoV-2 vaccine, specifically one or 392 more additional mRNA vaccine doses, anti-spike antibody levels increased significantly. These 393 data support recommendations from the Center for Disease Control regarding additional doses of 394

with moderate/severe forms of immune deficiency (30). Increased anti-spike antibody levels 396 following additional dose immunization were observed even in PAD patients with an 'at risk' 397 immunophenotype for poor response to initial series immunization (e.g., low class-switched 398 memory (CD27+IgM/D-) B cells). These data suggest a significant benefit to additional dose 399 vaccination in these patients with moderate to severe immune deficiency phenotypes. This 400 additional dose vaccine increased anti-spike antibodies to the level of matched controls following 401 initial series immunization. However, the optimal timing and number of vaccine doses needed to 402 prevent or mitigate disease in patients with PAD requires future studies. Additionally, there are 403

no data yet addressing the SARS-CoV-2 vaccine memory response in the PAD patient 404 demographic. Trends toward different isotype anti-RBD antibody responses between PAD 405 diagnoses may suggest that specific PAD patients are more predisposed to short-lived antibody 406 responses following SARS-CoV-2 vaccine. Data from patients with CVID have suggested an 407 extra-follicular or incomplete germinal center response to SARS-CoV-2 vaccination, yielding a 408 marked reduction in RBD-specific B cells (31). However, a dedicated follow-up study of the 409 SARS-CoV-2 humoral immune response over time in PAD patients is needed to address the 410 question of vaccine durability in this patient demographic. Finally, secondary 411 immunosuppression, specifically recent B-cell depletion therapy, was the only persistent risk 412 factor for a low (<100 U/mL) anti-spike antibody response following additional dose 413 immunization. These data suggest that additional doses of immunization may not be an adequate 414 strategy in this particular patient demographic and consideration of alternate options such as 415 tixagevimab/cilgavimab (Evusheld) for prophylaxis may be warranted. 416

A limitation to this study includes potential confounding from immunoglobulin 417 replacement that may contain antibodies to SARS-CoV-2 (27). Our analysis demonstrated that 418 no patients on immunoglobulin replacement had pre-vaccine anti-spike antibodies that met 419 criteria for minimal threshold response to vaccination, which was defined in our study as > 100 420 U/mL. These data suggest that passive antibody transfer from immunoglobulin replacement 421 therapy occurred, but at very low levels, at the time of this analysis. These data also highlight the 422 importance of effective vaccine counseling in this patient demographic, given that at the time of 423 this study, immunoglobulin replacement alone did not confer large amounts of antibodies against 424 SARS-CoV-2. It is expected that confounding from passive transfer of SARS-CoV-2 antibodies 425 in immunoglobulin replacement will increase over time, thus making future studies more 426 challenging. Other potential limitations include that this analysis was performed using data from 427 a large, but single healthcare system, so these findings may not be generalizable to other settings. 428

Additionally, there may be sampling bias in that differences may exist between those patients 429 who consented to be a part of this study versus those who did not. We found that SARS-CoV-2 430 (n=18) Ref.

Ref.

Ref.

Ref. shown in log scale and compared between PAD diagnoses as indicated. Symbols represent 501 unique individuals, bars represent geometric means (+/-95%CI) of total indicated patients (n), 502 and shading represents the assay lower limit of detection (LLD) or reactivity, respectively. * 503 p<0.05, ** p<0.01. 504 

Safety and 534 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and 536 Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Interim 538 Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Antibody responses to the SARS-CoV-2 vaccine in individuals with various Inborn Errors 542 of Immunity

Specific antibody 544 response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 545 2019 vaccination

COVID-19 vaccine in patients with inborn errors of immunity

Seroconversion after coronavirus disease 2019 vaccination in patients 550 with immune deficiency

552 Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Coronavirus disease 555 2019 in patients with inborn errors of immunity: An international study

Auto-antibodies against type I IFNs are associated with severe 558 COVID-19 pneumonia

Inborn errors of 560 type I IFN immunity in patients with life-threatening COVID-19

A possible role 562 for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Coronavirus disease 2019 in patients with inborn errors 565 of immunity: lessons learned

Minor Clinical 567 Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel

Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-571 Sectional Study

International Consensus Document (ICON): Common Variable 574 Immunodeficiency Disorders

Use and 576 interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of 577 the Basic and

Practice parameter 580 for the diagnosis and management of primary immunodeficiency

Human Inborn 583 Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification

State-of-the-art diagnostic evaluation of common 586 variable immunodeficiency

Comparative 588 Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-589

CoV-2 and Identify Individuals with High Neutralizing Titers

Search 591 of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 592 Assays in Pre-characterized Oligo-/Asymptomatic Patients

CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection 595 and Vaccination Adaptive Immune Responses

Comparative immunogenicity and effectiveness of mRNA-1273

S COVID-19 vaccines. medRxiv. 2021

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. 601 Cell

603 Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Anti-SARS-CoV-2 antibodies in healthy donor plasma 605 pools and IVIG products

Variable Immunodeficiency Non-Infectious Disease Endotypes Redefined Using Unbiased 608 Network Clustering in Large Electronic Datasets

Humoral and 610 cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-611 cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does 619 their Best

Memory T cell 621 responses targeting the SARS coronavirus persist up to 11 years post-infection

Intrafamilial 624 Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion